Inflammatory, Atherosclerosis/Cardiovascular Signature in Atopic Dermatitis
Skin rather than blood is the primary source for the inflammatory and atherosclerosis/cardiovascular signature, data from this novel study suggests.
Atopic Dermatitis
Pediatric Atopic Dermatitis Linked to Clinically Significant Mental Health Symptoms
Atopic dermatitis is associated with clinically significant mental health symptoms, but nearly half of children with atopic dermatitis and severe mental health impairments may not receive mental healthcare, suggesting a critical practice gap.
PO SCORAD for Black Skin a Valuable Tool for Evaluating AD
PO-SCORAD for black skin is a simple tool that allows patients to easily self-assess atopic dermatitis severity. It may prove a valuable tool for monitoring disease severity between physician visits and involving patients in the management of their disease.
The Role of Gut Microbiome in Inflammatory and Allergic Skin Diseases
This review gives insight into the role of gut microbiome alterations in the pathogenesis of psoriasis, acne, rosacea, hidradenitis suppurativa, and atopic dermatitis.
Pharmacotherapy Trends for Atopic Dermatitis in the US
Although the atopic dermatitis treatment patterns found reflect existing clinical guidelines, second-generation antihistamines are not recommended in the management of atopic dermatitis, despite being the third most prescribed medication class.
Expert Roundtable: Comorbidities in Atopic Dermatitis
Atopic dermatitis, especially severe atopic dermatitis, is associated with allergic, autoimmune, and cardiovascular comorbidities.
Dupilumab Induces Rapid Improvement of Atopic Dermatitis in Japanese Adults
Data from this analysis indicate that dupilumab induces rapid improvements in AD that can be maintained long term in a significant percentage of Japanese adults with moderate to severe AD, with prolonged benefits in terms of both pruritus and QoL.
Moderate to Severe Atopic Dermatitis Associated With Increased Risk for Atrial Fibrillation
The study data showed a 20% increased long-term risk for atrial fibrillation in patients with hospital-diagnosed moderate to severe atopic dermatitis.
Abrocitinib Effective in Second Phase 3 Atopic Dermatitis Trial
Pfizer announced positive topline results from the phase 3 JADE MONO-2 trial of abrocitinib, an oral Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis.
Jynneos Gets FDA Approval for Smallpox, Monkeypox Prevention
The FDA has approved Jynneos (smallpox and monkeypox vaccine, live, non-replicating; Bavarian Nordic) for the prevention of smallpox and monkeypox in adults 18 years of age and older determined to be at high risk for these infections.
Next post in General Dermatology
